Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biobased Chemicals

Antheia to access Ginkgo’s enzyme screening and design technology

by Rick Mullin
August 19, 2021 | A version of this story appeared in Volume 99, Issue 30

Ginkgo Bioworks, a Boston-based cell-programming specialist, will deploy its high-throughput enzyme design and screening technology to help the synthetic biology firm Antheia broaden its pipeline of drug active ingredients and starting materials. Antheia recently raised $73 million to advance its method for making complex molecules in yeast. Meanwhile, Ginkgo and Aldevron say they have made progress in their partnership to optimize Aldevron’s production of messenger RNA vaccine components.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.